Confidential Materials omitted and filed separately with the
Securities and Exchange Commission. Asterisks denote omissions.
This Amendment (the “ Amendment ”) to the License Agreement dated as of December 18, 2003 by and
(1) ASTRAZENECA AB, a company incorporated under the laws of Sweden with its registered office at
SE-151 85 Södertälje, Sweden (“ASTRAZENECA”) (“ AstraZeneca ”); and
(2) The MEDICINES COMPANY, a company incorporated under the laws of Delaware with its
registered office at 8 Campus Drive, Parsippany, New Jersey 07054, United States (“TMC”).
(the “ Agreement ”) is made effective as of July 6, 2007 (the “ Amendment Effective Date ”).
WHEREAS, the Parties desire to amend, modify and restate certain terms and conditions of the Agreement.
NOW, THEREFORE, in consideration of the mutual covenants contained in this Amendment, and other
good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the
Parties, intending to be legally bound, agree as follows:
1 Definitions .
Any capitalized term not separately defined in this Amendment shall have the meaning ascribed to it in the
2.1 Article 3.7.2 of the Agreement shall be amended to read as follows:
“3.7.2 Time Limit for Filing of an NDA.
a) TMC shall no later than [**] have made a Filing of an NDA [**]
b) TMC shall no later than [**] or [**] after having made a Filing of an NDA in
the United States, whichever is the earlier, have made a Filing of an NDA [**].
c) TMC shall no later than [**] or [**] after having made the last Filing of an NDA under
Article 3.7.2 (b), whichever is the earlier, have made a Filing of an NDA [**].”
2.2 Articles 5.1.1 and 5.1.2 of the Agreement shall be amended to read as follows: